Chronic Glomerulonephritis Follow-up

  • Author: Moro O Salifu, MD, MPH, FACP; Chief Editor: Vecihi Batuman, MD, FACP, FASN   more...
 
Updated: Jan 12, 2012
 

Further Inpatient Care

Patients with CKD admitted to the hospital should have careful monitoring of weight, intake, output, and renal function so that acute renal failure, if it occurs, can be diagnosed and treated early. All potentially nephrotoxic agents must be adjusted for the degree of CKD. Furthermore, agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, and intravenous contrast, must be avoided, unless the benefits clearly outweigh the risks, because these agents are highly associated with acute renal failure.

Next

Further Outpatient Care

Patients with any evidence of kidney disease should be referred to a kidney specialist (nephrologist). Data suggest that early referral to a nephrologist improves the overall outcome. The nephrologist will usually determine the frequency of visits based on the degree of CKD.

Previous
Next

Complications

  • The presence of the following complications generally indicates a need for urgent dialysis:
    • Metabolic acidosis
    • Pulmonary edema
    • Pericarditis
    • Uremic encephalopathy
    • Uremic gastrointestinal bleeding
    • Uremic neuropathy
    • Severe anemia and hypocalcemia
    • Hyperkalemia
Previous
Next

Prognosis

The prognosis depends on the type of chronic glomerulonephritis (see Causes).

Previous
Next

Patient Education

  • For further information, see Mayo Clinic - Kidney Transplant Information.
  • Dietary education is paramount in managing patients with CKD. The typical dietary restriction is 2 g of sodium, 2 g of potassium, and 40-60 g of protein a day. Additional restrictions may apply for diabetes, hyperlipidemia, and fluid overload.
  • Patients should be educated regarding the types of ESRD therapy. The specific choices of ESRD therapy include hemodialysis, peritoneal dialysis, and renal transplantation.
    • Patients opting for hemodialysis should be educated on home hemodialysis (ie, patients are trained to do their dialysis at home) and center hemodialysis (ie, patients must come to a center 3 times a week for 3.5- to 4-hour dialysis sessions). They should also be educated on the types of vascular access. Arteriovenous fistulae should be created when the GFR falls below 25 mL/min or the serum creatinine level is greater than 4 mg/dL to allow for maturation of the access prior to the initiation of dialysis.
    • Peritoneal dialysis catheters can be placed if dialysis is anticipated within 2-3 weeks.
    • Preemptive transplantation before the initiation of dialysis improves survival as compared with transplantation after the initiation of dialysis; therefore, preemptive transplantation should be explored from live donors. In patients without live donors, they can be placed on the deceased donor wait list when the GFR falls below 20 mL/min to accrue time. Patients who opt for no treatment when it is indicated should be informed of imminent renal failure in a shorter time.
  • In the United States and most developed countries, patients on dialysis can travel. In fact, there are even dialysis cruises. However, patients should inform their social workers to make the necessary arrangements prior to any travel to ensure that the destination has the right resources to continue dialysis.
  • Sexual dysfunction and loss of libido is common in patients with kidney disease, especially in men. Patients should be told to seek medical therapy if they experience these symptoms.
Previous
 
Contributor Information and Disclosures
Author

Moro O Salifu, MD, MPH, FACP  Associate Professor, Department of Internal Medicine, Chief, Division of Nephrology, Director of Nephrology Fellowship Program and Transplant Nephrology, State University of New York Downstate Medical Center

Moro O Salifu, MD, MPH, FACP is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Artificial Internal Organs, American Society of Diagnostic and Interventional Nephrology, American Society of Nephrology, American Society of Transplantation, and National Kidney Foundation

Disclosure: Nothing to disclose.

Coauthor(s)

Barbara G Delano, MD, MPH  Director of Home Hemodialysis and Peritoneal Dialysis, Professor, Department of Internal Medicine, Division of Nephrology, State University of New York at Brooklyn

Barbara G Delano, MD, MPH is a member of the following medical societies: American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, and Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

Frank C Brosius III, MD  Nephrology Program Director, Professor of Internal Medicine and Physiology, Department of Internal Medicine, Division of Nephrology, University of Michigan School of Medicine

Frank C Brosius III, MD is a member of the following medical societies: Alpha Omega Alpha, American Diabetes Association, American Society of Nephrology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

George R Aronoff, MD  Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

Rebecca J Schmidt, DO, FACP, FASN  Professor of Medicine, Section Chief, Department of Medicine, Section of Nephrology, West Virginia University School of Medicine

Rebecca J Schmidt, DO, FACP, FASN is a member of the following medical societies: American College of Physicians, American Medical Association, American Society of Nephrology, International Society of Nephrology, National Kidney Foundation, Renal Physicians Association, and West Virginia State Medical Association

Disclosure: Renal Ventures Ownership interest Other

Chief Editor

Vecihi Batuman, MD, FACP, FASN  Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Medicine Service, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, and International Society of Nephrology

Disclosure: Nothing to disclose.

References

  1. Kawasaki Y. Mechanism of onset and exacerbation of chronic glomerulonephritis and its treatment. Pediatr Int. Dec 2011;53(6):795-806. [Medline].

  2. Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. Dec 7 2011;[Medline].

  3. Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. Oct 2009;24(10):3068-74. [Medline].

  4. Idasiak-Piechocka I, Oko A, Pawliczak E, Kaczmarek E, Czekalski S. Urinary excretion of soluble tumour necrosis factor receptor 1 as a marker of increased risk of progressive kidney function deterioration in patients with primary chronic glomerulonephritis. Nephrol Dial Transplant. Dec 2010;25(12):3948-56. [Medline].

  5. Hayakawa K, Ohashi H, Yokoyama H, et al. Adiponectin is increased and correlated with the degree of proteinuria, but plasma leptin is not changed in patients with chronic glomerulonephritis. Nephrology (Carlton). Apr 2009;14(3):327-31. [Medline].

  6. Wolf G. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis. Nat Clin Pract Nephrol. Sep 2008;4(9):474-5. [Medline].

  7. Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. Sep 2007;2(5):906-13. [Medline].

  8. Omae K, Ogawa T, Nitta K. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. Heart Vessels. Jul 2009;24(4):301-7. [Medline].

  9. Blowey DL, Warady BA. Outcome of infants born to women with chronic kidney disease. Adv Chronic Kidney Dis. 2007;14:199-205. [Medline].

  10. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR. Identification and referral of patients with progressive CKD: a national study. Am J Kidney Dis. 2006;48:192. [Medline].

  11. Cameron JS. The Long-Term Outcome of Glomerular Diseases. In: Schrier RW, Gottschalk CW, ed. Diseases of the Kidney. 6th ed. Little, Brown & Company: Boston, Mass; 1997:1919.

  12. Campbell NR, Burgess E, Choi BC, Taylor G, Wilson E, Cléroux J, et al. Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Lab Centre for Disease Control. CMAJ. May 4 1999;160(9 Suppl):S1-6. [Medline].

  13. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. Mar 4 2004;350(10):971-80. [Medline].

  14. Coppo R, Gianoglio B, Porcellini MG, Maringhini S. Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Nephrol Dial Transplant. Feb 1998;13(2):293-7. [Medline].

  15. Coresh J, Walser M, Hill S. Survival on dialysis among chronic renal failure patients treated with a supplemented low-protein diet before dialysis. J Am Soc Nephrol. Nov 1995;6(5):1379-85. [Medline].

  16. Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. Nov 2000;26(3):354-7. [Medline].

  17. Imbasciati E, Gregorini G, Cabiddu G, Gammaro L, Ambroso G, Del Giudice A, et al. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis. 2007;49:753-62. [Medline].

  18. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131-40. [Medline].

  19. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. Feb 2002;39(2 Suppl 1):S1-266. [Medline].

  20. Levy M, Berger J. Worldwide perspective of IgA nephropathy. Am J Kidney Dis. Nov 1988;12(5):340-7. [Medline].

  21. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. Mar 2004;24(2):168-75. [Medline].

  22. Nakai S, Wada A, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial. 2006;10:476-97. [Medline]. [Full Text].

  23. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361(9352):117-24. [Medline].

  24. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: a paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. Mar 1998;31(3):398-417. [Medline].

  25. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. Nov 15 1995;123(10):754-62. [Medline].

  26. Polenakovic M, Grcevska L. Survival rate of patients with glomerulonephritis. Acta Med Croatica. 1992;46(1):15-20. [Medline].

  27. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. Nov 12 1998;339(20):1448-56. [Medline].

  28. Remuzzi G, Chiurchiu C, Ruggenenti P. Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int Suppl. Nov 2004;(92):S90-6. [Medline].

  29. Research Group on Progressive Chronic Renal Disease. Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. Nephron. 1999;82(3):205-13. [Medline].

  30. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-51. [Medline].

  31. Schöll U, Wastl U, Risler T, Braun N, Grabensee B, Heering P, et al. The "point of no return" and the rate of progression in the natural history of IgA nephritis. Clin Nephrol. Nov 1999;52(5):285-92. [Medline].

  32. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. Sep 2004;66(3):1199-205. [Medline].

  33. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67:799-812. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.